MedStar Authors catalog › Details for: Epidemiology and Outcomes of Hospitalizations With Invasive Aspergillosis in the United States, 2009-2013.
Normal view MARC view ISBD view

Epidemiology and Outcomes of Hospitalizations With Invasive Aspergillosis in the United States, 2009-2013.

by Shorr, Andrew F.
Citation: Clinical Infectious Diseases. 2018 Apr 28; Clinical Infectious Diseases. 67(5):727-735, 2018 08 16..Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.Published: 2018ISSN: 1058-4838.Full author list: Harrington R; Nathanson BH; Shorr AF; Spalding JR; Zilberberg MD.UI/PMID: 29718296.Subject(s): *Aspergillosis/mo [Mortality] | *Hospital Mortality | *Hospitalization/ec [Economics] | *Invasive Fungal Infections/ec [Economics] | *Invasive Fungal Infections/mo [Mortality] | Aged | Aged, 80 and over | Aspergillosis/ec [Economics] | Cost of Illness | Female | Humans | Length of Stay/ec [Economics] | Male | Middle Aged | Patient Discharge | Patient Outcome Assessment | Patient Readmission/sn [Statistics & Numerical Data] | Propensity Score | Retrospective Studies | United States/ep [Epidemiology]Institution(s): MedStar Washington Hospital CenterDepartment(s): Medicine/Pulmonary-Critical CareActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1093/cid/ciy181 (Click here) Abbreviated citation: Clin Infect Dis. 2018 Apr 28; Clin Infect Dis. 67(5):727-735, 2018 08 16.Local Holdings: Available online from MWHC library: June 1997 - present, Available in print through MWHC library: 1999 - Winter 2007.Abstract: Background: Though invasive aspergillosis (IA) complicates care of up to 13% of patients with immunocompromise, little is known about its morbidity and mortality burden in the United States.Abstract: Conclusions: Although rare even among high-risk groups, IA is associated with increased hospital mortality and 30-day readmission rates, excess duration of hospitalization, and costs. Given nearly 40000 annual admissions for IA in the United States, the aggregate IA-attributable excess costs may reach Abstract: Methods: We analyzed the Health Care Utilization Project's data from the Agency for Healthcare Research and Quality for 2009-2013. Among subjects with high-risk conditions for IA, IA was identified via International Classification of Diseases, Ninth Revision, Clinical Modification codes 117.3, 117.9, and 484.6. We compared characteristics and outcomes between those with (IA) and without IA (non-IA). Using propensity score matching, we calculated the IA-associated excess mortality and 30-day readmission rates, length of stay, and costs.Abstract: Results: Of the 66634683 discharged patients meeting study inclusion criteria, 154888 (0.2%) had a diagnosis of IA. The most common high-risk conditions were major surgery (50.1%) in the non-IA and critical illness (41.0%) in the IA group. After propensity score matching, both mortality (odds ratio, 1.43; 95% confidence interval, 1.36-1.51) and 30-day readmission (1.39; 1.34-1.45) rates were higher in the IA group. IA was associated with 6.0 (95% confidence interval, 5.7-6.4) excess days in the hospital and

Powered by Koha